Alveolar Soft Part Sarcoma: A Single-Center 26-Patient Case Series and Review of the Literature by Ogura, Koichi et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 907179, 6 pages
doi:10.1155/2012/907179
Clinical Study
Alveolar Soft Part Sarcoma: A Single-Center 26-Patient Case
Seriesand Reviewof the Literature
Koichi Ogura,1,2 Yasuo Beppu,1 Hirokazu Chuman,1 Akihiko Yoshida,3 Noboru Yamamoto,4
Minako Sumi,5 HirotakaKawano,2 andAkiraKawai1
1Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Department of Orthopaedic Surgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
3Division of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
4Division of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
5Division of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Correspondence should be addressed to Akira Kawai, akawai@ncc.go.jp
Received 15 November 2011; Revised 9 February 2012; Accepted 13 March 2012
Academic Editor: Alessandro Gronchi
Copyright © 2012 Koichi Ogura et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Alveolar soft part sarcoma (ASPS) is a rare tumor, and little information is available regarding its clinical features
and appropriate treatments. Methods. A retrospective review of 26 consecutive ASPS patients (12 male, 14 female; mean age of 27
years) treated at our institution over 30 years (mean followup; 71 months) was performed. Results. The primary tumor developed
in the lower extremity (12), trunk (8), and upper extremity (6), with an average size of 7.2 cm (range, 2–14cm). The AJCC stage
at presentation was IIA (7), III (3), and IV (16). Surgical excision was performed in 20 patients (R0 18, R1 plus radiotherapy
2) without local recurrence. Six patients (stage IIA 3/7, stage III 3/3) later developed metastases after an average period of 28.7
months. The median survival of the 26 patients was 90 months, with overall 5/10-year survival rates of 64%/48%. AJCC stage
and tumor size were signiﬁcant prognostic factors. Signiﬁcant palliation and slowing of metastasis progression were achieved with
gamma knife radiotherapy. Nine patients receiving chemotherapy showed no objective response. Conclusions. ASPS is indolent
but has a high propensity for metastasis. Early diagnosis and complete excision of the small primary tumor are essential in the
treatment of ASPS.
1.Introduction
Alveolar soft part sarcoma (ASPS) is a rare tumor that was
initially described as a distinctive clinical entity by Christo-
pherson et al. in 1952 [1]. It accounts for approximately 0.5–
1% of all soft tissue sarcomas and aﬀects mainly adolescents
and young adults [2]. The name “alveolar” was derived
from its pseudoalveolar appearance with clustered polygonal
cells lacking central cohesion. ASPS tumor cells exhibit
characteristic PAS-positive, diastase-resistant, intracytoplas-
mic rhomboid crystals that contain monocarboxylate trans-
porter 1 and CD147 [3]. Molecular cytogenic studies of
ASPS have demonstrated the chromosome rearrangement
der(17)t(X;17)(p11;q25) resulting in the ASPL-TFE3 fusion
gene, which is highly speciﬁc and critical for development of
the tumor [4]. In spite of these advances in basic research,
the origin/diﬀerentiation of ASPS still remains obscure, and
nooptimaloreﬀectivetreatmenthasbeendevised,especially
for advanced cases.
The main obstacle to gaining a thorough understanding
of the clinical behavior and optimal treatment of ASPS is
the rarity of the disease. The majority of previous reports
have been in the form of small collective series from referral
centers or multi-institutional studies over a long period
(Table 1)[ 5–15]. Most series have suggested that ASPS is
resistant to conventional cytotoxic chemotherapy and sup-
port the contention that complete excision of the tumor
is the only meaningful treatment for ASPS. Moreover, data
regarding the clinical value of radiotherapy for treatment of
ASPS are still limited [5–13].
With this background in mind, we conducted the present
study of 26 consecutive patients with ASPS treated at2 Sarcoma
Table 1: Clinicopathologic studies of ASPS.
Reference Year No. of patients 5-year survival (%) Prognostic factor
All M0 M1
Evans [14] 1985 13 60 NA NA Size
Auerbach and Brooks [6] 1987 20 67 NA NA NA
Lieberman et al. [9] 1989 91 57 60 22 Age, AJCC stage
Pappo et al. [11] 1996 11∗ 88 NA NA None
Casanova et al. [7] 2000 19∗ 80 91 NA Size
Portera et al. [12] 2001 70 47 88 20 AJCC stage
Van Ruth et al. [15] 2002 15 38 48 NA NA
Ogose et al. [10] 2003 57∗∗ 56 81 46 AJCC stage, size, bone involvement
Anderson et al. [5] 2005 15 75 NA NA None
Daigeler et al. [8] 2008 11 88 88 — None
Pennacchioli et al. [13] 2010 33 69 NA NA Size, surgical margin
Current study 26 64 100 37 AJCC stage, size
NA indicates not available.
∗All patients are pediatric patients.
∗∗Patients from 27 institutions.
our institution during the era of modern multidisciplinary
treatment with a view to seeking a new or ideal form of
treatment for the disease.
2. Patientsand Methods
Between 1979 and 2008, 26 consecutive patients with
ASPS were treated at our institution. Their clinical data,
histopathological ﬁndings, treatment modalities, and treat-
ment outcome were reviewed retrospectively. The followup
period ranged from 8 to 311 months with an average of 71
months.
Thepatientsunderwentmultimodalitytreatmentinclud-
ing surgery, radiotherapy, and chemotherapy depending on
the individual tumor stages. We attempted wide excision of
the primary tumor to achieve a negative surgical margin
whenever possible. The surgical margin was examined his-
tologically at the point closest to the resected specimen, and
was classiﬁed as R0 (negative, no tumor cells on the inked
margin) or R1 (positive, tumor cells on the inked margin).
Radiotherapy was used in patients who were at high risk of
local recurrence after R1 excision (adjuvant radiotherapy) or
inpatientswhohadadvancedormetastaticdisease(palliative
radiotherapy). Chemotherapy was administered to patients
with metastatic disease using a variety of regimens (mainly
anthracycline-containing regimens). Tumor response was
judged from ﬁndings of plain radiography, computed
tomography (CT), and magnetic resonance imaging (MRI)
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) [16].
The following demographic and treatment factors were
examined for prognostic importance: patient age (≤30 years
or >30 years, ≤18 years or >18 years), gender, tumor
size (≤5cmor>5cm), tumor location and depth, surgical
margin, and American Joint Committee on Cancer (AJCC)
staging [17]. Tumor depth was classiﬁed as superﬁcial or
deep in relation to the investing fascia.
Continuous data were summarized as means or medians
unless noted otherwise, while discrete (or categorical) data
were summarized as counts (percentages). Overall, local
recurrence-free and distant metastasis-free survivals were
calculated using the Kaplan-Meier method. Univariate anal-
ysis was performed by log rank analysis. Diﬀerences at P<
0.05 were considered signiﬁcant. Statistical analyses were
performed using the Statview 5.0 statistical package (SAS
Institute Inc., Cary, NC). This study was approved by the
institutional review board of National Cancer Center.
3. Results
3.1. Clinical Characteristics. The study group comprised 12
men (mean age of 30 years) and 14 women (mean age of 24
years) with an average age at diagnosis of 27 years (range,
2–46 years). There was a slight female preponderance in our
series, and this tendency was more striking in the patients
aged ≤30 years (4 males and 10 females). On the other hand,
there was male preponderance among the patients aged >30
years (8 males and 4 females). The primary tumors were
located in the lower extremity (n = 12), trunk (n = 8),
and upper extremity (n = 6) and averaged 7.2cm (range,
4–14cm) in largest diameter. Twenty ﬁve tumors were deep-
seated and one was superﬁcial. Most patients (n = 23)
presented with a painless mass, two with asymptomatic lung
metastasesfoundataperiodicmedicalexamination,andone
with painful rib metastases. Ten patients (38%) presented
with localized disease and 16 (62%) with metastatic disease:
lung in 15, bone in 3, and brain in 2. According to the AJCC
staging [17], 7 patients were classiﬁed as stage IIA, 3 as stage
III, and 16 as stage IV.
3.2. Treatment. Surgical excision of the primary tumor was
performed in 20 patients. The surgical margin was classiﬁed
as R0 in 18 and R1 in 2. The two patients with an R1 margin
received adjuvant radiotherapy (preoperative radiotherapySarcoma 3
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Figure 1: Kaplan-Meier plots showing overall survival of the 26
patients with ASPS.
(46.2Gy) in one, and postoperative brachytherapy (36Gy)
in the other) [18]. No local recurrence was seen in these 20
patients during a mean followup period of 81 months.
Two patients with stage IV disease underwent only
biopsy of the primary tumor and showed slow but gradual
progression of the primary tumor during followup. Four
patients with stage IV disease received radiotherapy (40–
66Gy) as the only treatment for the primary tumor because
of the advanced nature of their disease. None of these 4
patients showed progression of the irradiated primary tumor
untilthetimeofdeathorlastfollowup(13–24months;mean
20.5 months).
Chemotherapy in various combinations (including dox-
orubicin, ifosfamide, cyclophosphamide, cisplatin, etopo-
side, gemcitabine, and docetaxel) was administered to 9
patients with stage IV disease. No objective clinical response
was observed (SD in 2, PD in 6 patients) in all of the 8
patients with measurable disease.
Five patients with localized disease ultimately developed
metastases. Altogether, 21 (81%) of the 26 patients had
metastatic disease, either at presentation or developing later.
Thesitesofmetastasesincludedthelungin20patients,brain
in 11, bone in 7, liver in 3, and spleen in 2.
3.3. Survival. The median survival of the 26 patients was 90
months,withoverall5-and10-yearsurvivalratesof64%and
48%, respectively (Figure 1). Median survival for those with
stage IV disease was 41 months. The 5-year local recurrence-
free, metastasis-free, and overall survival rates for patients
with localized disease at presentation were 100%, 33%, and
100%, respectively. Univariate analysis showed that tumor
size (P = 0.014) and AJCC stage (P = 0.005) were signiﬁcant
prognostic factors for overall survival (Figure 2, Table 2).
4. Discussion
ASPS is an extremely rare tumor that accounts for approx-
imately 0.5–1% of all soft tissue sarcomas [2]. The rarity of
the tumor makes it diﬃcult to draw deﬁnitive conclusions
regarding its clinical characteristics, prognostic factors, and
appropriatetreatment.Themajorityofpreviousreportshave
been in the form of case reports or small collective series
[5–15]. The present study is one of the largest series based
on data from a single referral center in the era of modern
multidisciplinary treatment [9, 12, 13].
The mean patient age at diagnosis was 27 years, and
a slight female preponderance (54%) was observed overall.
Interestingly, among the 14 patients aged ≤30 years, there
was a striking female preponderance (10 female patients,
71%), in contrast to a male preponderance among the 12
patients aged >30 years (4 female patients, 33%). Such an
age-related gender ratio inversion was also described in two
previous series from the Memorial Sloan-Kettering Can-
cer Center and MD Anderson Cancer Center [9, 12]. As
this phenomenon appears to be exceptional in the ﬁeld of
sarcoma/cancer epidemiology, we retrieved data from the
nationwide bone and soft tissue tumor (BSTT) registry in
Japan [19]. In the prospectively collected BSTT database, we
found67patientswithASPS(30males(45%)and37females
(55%)) diagnosed during the period of 2002 to 2009. The
same age-related gender ratio inversion was found in this
nationwide cohort. Among the 40 patients aged ≤30 years,
therewasadeﬁnitefemalepreponderance(27females,68%),
in contrast to a male preponderance among the 27 patients
aged >30 years (10 females, 37%).
ASPS has a nonreciprocal chromosomal translocation
der(17)t(X;17)(p11;q25) with the corresponding oncogenic
fusion gene, ASPL-TFE3 [20]. Because females have an
extra X-chromosome, their likelihood of developing an X-
autosome translocation is theoretically double that of males.
Recently, Bu and Berstein have proposed that the female
preponderance in ASPS may be a result of having two X-
chromosomes with a fusion gene that is not subject to X-
inactivation. Although a mathematical model based on pop-
ulation-based SEER registry data has supported their hypo-
thesis in ASPS as a whole, it alone is unable to account for
the observed age-related gender ratio inversion. It seems that
additional and/or alternative mechanisms such as hormonal
eﬀects might be involved in this intriguing phenomenon.
There is little information available in the literature
regardingprognosticfactorsinASPS(Table 1)[5–15].Inour
series, tumor size and AJCC stage were signiﬁcant prognostic
factors for overall survival of patients with ASPS. The impact
of tumor size on the prognosis of ASPS has also been
reported in previous studies [7, 10, 13].
An eﬀect of tumor size on the outcome of soft tissue
sarcoma has been extensively demonstrated. In general, in
soft tissue sarcomas, tumor size indirectly reﬂects the rapid-
ity of tumor growth and tumor biological aggressiveness.
However, considering the indolent tumor growth of ASPS,
this concept does not appear to be applicable. In ASPS, a
larger tumor might reﬂect a longer disease history, and thus
a higher likelihood of systemic spread. Indeed, in our series,
there was a signiﬁcant correlation between tumor size and
presence of metastases; 3 of 10 patients (30%) with tumors
≤5cm in largest diameter presented with localized disease
(AJCC stage IIA or III), whereas 12 of 15 patients (80%) with
tumors measuring >5cm presented with metastatic disease
(AJCC stage IV) (P = 0.001, chi-squared test).4 Sarcoma
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Figure 2: Kaplan-Meier plots showing overall survival stratiﬁed by (a) tumor size (>5cm: solid line, ≤5cm: dashed line) and (b) AJCC stage
(stage IIA, III: solid line, stage IV: dashed line).
Table 2: Potential risk factors for overall survival.
Factor No. of patients 5-year survival P-value
Gender
Male 12 80 0.57
Female 14 50
Age at diagnosis
≤30 years 14 66 0.21
>30 years 12 61
≤18 years 7 83 0.11
>18 years 19 57
Tumor size
≤5 cm 10 89 0.014
>5c m 1 5 5 3
Location 1
Upper extremity 6 83 0.31
Lower extremity 12 58
Trunk 8 69
Depth
Deep 25 62 NA
Superﬁcial 1 100
The AJCC stage
IIA/III 10 100 0.005
IV 16 38
Surgical margin
R0 18 63 0.91
R1 2 50
Although statistically not signiﬁcant, younger age (≤18
years) at diagnosis was associated with a favorable outcome
in our series. Some previous reports have also indicated that
pediatric ASPS has a more favorable prognosis than its adult
counterpart [9, 11]. Diﬀerences in biological characteristics
between pediatric and adult ASPS have been proposed to
explain the better prognosis of pediatric ASPS [7, 9]. In
ASPS, a larger tumor size, as described above, is a prognostic
factor that impacts on survival. In our series, the tumor at
presentation showed a tendency to be smaller in pediatric
patients (age ≤18 years) than in adult patients (age >18
years); only 1 of 6 pediatric patients (17%) presented with a
tumor measuring >5cm, while 14 of 19 adult patients (74%)
did so (P = 0.001, chi-squared test). Our data indicate that
the age-related diﬀerence in prognosis may be attributable to
a larger tumor size, resulting in an increased risk of distant
metastases in adult patients.
Local recurrence after excision of ASPS was reportedly
as high as 20% in the largest series of 91 patients treated
at the Memorial Sloan-Kettering Cancer Center [9]. Evans
noted a higher local recurrence rate of 31% [14]. In contrast,
Portera et al. and van Ruth et al. reported that the local
recurrence rate of ASPS after surgical excision was around
10% [12, 15]. The risk factors for local recurrence in ASPS
have not been clariﬁed. Ogose et al. reported that none of
38 patients who underwent wide excision of ASPS developed
local recurrence, in contrast to 4 out of 7 patients who
underwent marginal excision without radiotherapy [10]. In
our series, no local recurrence was observed in 18 patients
who underwent tumor excision with an R0 margin. These
results suggest that R0 excision is essential (and perhaps
suﬃcient) for achieving satisfactory local control of ASPS.
None of the patients who underwent R1 excision plus
adjuvant radiotherapy developed local recurrence in the
present series. Although it is impossible to draw deﬁnitive
conclusions about the eﬀectiveness of adjuvant radiotherapy
for ASPS based on the limited number of patients in our
series, several studies have suggested that adjuvant radio-
therapy is beneﬁcial in this setting. Sherman et al. reported
prolonged(24–150months)localcontrolinallofsixpatients
who underwent surgery and adjuvant radiotherapy (56–
65Gy) [21]. Anderson et al. also reported good local control
(no local recurrence) of the primary tumor in 14 patients
with ASPS after wide excision and adjuvant radiotherapy
(45–72Gy) [5]. Moreover, some of their patients showed no
progression of the primary tumor after radiotherapy alone
without surgery. The beneﬁt of radiotherapy for patientsSarcoma 5
with ASPS appears attributable to enhanced local control
after surgery with inadequate or close resection margins.
ASPS shows a high incidence (around 30%) of brain
metastases, being at least 3 times higher than that of
other soft tissue sarcomas [22]. Although it remains
unclear whether this high incidence of brain metastases
is attributable to disease-speciﬁc biology or a long disease
duration, the survival of patients after diagnosis of brain
metastases remains poor (median survival 12 months).
As almost all brain metastases have been associated with
metastatic spread to extracranial sites such as the lung,
surgical treatment is not usually indicated. In our series,
four patients with brain metastases underwent gamma knife
radiotherapy and achieved satisfactory local control of the
disease, with a median progression-free time of 12 months
(range, 9–30 months). It is striking that all 4 patients were
alive without local disease progression at the time of last
followup. Although larger prospective studies are important
for clarifying speciﬁc types of patients who would beneﬁt
from this type of radiotherapy, it is expected to become the
treatment of choice for those with brain metastases from
ASPS.
In the present series, none of the patients responded to,
orbeneﬁtedsigniﬁcantlyfrom,conventionalchemotherapies
includingacombinationofgemcitabineanddocetaxel.These
results are concordant with the widely accepted concept
that conventional cytotoxic agents such as doxorubicin,
ifosfamide, and dacarbazine have little eﬃcacy in ASPS [5–
12]. Reports of tumor responses to interferon alpha (IFN-α)
have been anecdotal [23–25]. It is apparent that alternative
therapeutic strategies/agents are necessary for patients with
advanced ASPS.
The feasibility of using an antiangiogenic agent for the
treatmentofASPSwasdemonstratedbyVisticaetal.usingin
vivo preclinical models [26]. They observed upregulation of
angiogenesis-related genes in an ASPS xenograft model and
demonstratedthatacombinationofbevacizumab(ahuman-
ized antiVEGFα monoclonal antibody) and topotecan (a
topoisomerase 1 inhibitor with antiangiogenic properties)
slowed the growth of the tumor by 70%. Recently, it has
been reported that several antiangiogenic agents such as
bevacizumab and sunitinib malate exert tumor-suppressive
eﬀects in ASPS [26–30].
Notably, we found that cediranib (AZD2171), a potent
oral inhibitor of VEGFR tyrosine kinases that blocks the el-
aboration of new blood vessels, elicited signiﬁcant tumor
shrinkage with a progression-free survival period of 27
months (data not shown). Cediranib has been identiﬁed
as having substantial single-agent antitumor activity against
ASPS in early-phase clinical trials that included 7 patients
[30]. Another recent larger phase II study has demonstrated
preliminarilythatcediranibhaspromisingactivityandsafety
with a response rate of >40% and a disease control rate
(PR+SD) at 6 months of 78% [28]. Given these data, an
antiangiogenic approach seems to be promising and may
become a breakthrough treatment for management of ad-
vanced ASPS.
In conclusion, ASPS is relatively indolent but has a
high propensity for metastasis. Early diagnosis and complete
excision of a small primary tumor is important in the treat-
ment of ASPS. Antiangiogenic strategies may become a
breakthrough form of management for advanced ASPS.
We propose that patients with metastatic ASPS should be
enrolled in prospective clinical trials to assess the eﬀective-
ness of new treatments such as antiangiogenic therapy.
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